Dr. Davoli obtained her Ph.D. in 2013 from The Rockefeller University working with Dr. Titia de Lange on studying telomere. During her postdoctoral training, she worked with Dr. Stephen Elledge using genomics approaches to understand the consequences of cancer aneuploidy for tumor formation and immune evasion. In May 2018, Dr. Davoli started her lab at the Institute for Systems Genetics at NYU School of Medicine in New York. Throughout her career, Dr Davoli has combined functional genetics and computational approaches to genomic instability in cancer. Dr. Davoli found that tumors with a high level of aneuploidy tend to be immune cold and to be refractory to immunotherapy (Davoli et al., Science 2017). Through collaborative efforts with Dr. Scott Lippman and others, her lab found that tumors bearing 9p loss tend to be immune cold and to be refractory to immunotherapy (William et al., PNAS 2021 and Zhao et al. PNAS, 2022). Finally, her lab more recently described a method called KaryoCreate to experimentally engineer specific chromosomal aneuploidies in human cells which has the potential to foster our understanding of aneuploidy in human cancer and beyond (Bosco et al., Cell 2023).  Dr. Davoli has received the Weintraub Graduate Student award in 2013 and she was a Helen Hay Whitney Postdoctoral Scholar. Dr. Davoli was also awarded the Breast Cancer Alliance Young Investigator Award, the V Foundation Scholar Award, the Melanoma Research Association, Melanoma Research Alliance Young Investigator Award, the V Foundation Scholar Award, the R37 NIH MERIT Award and the Pershing Square Sohn Prize for Young Investigators in Cancer Research.